For other salt forms or metabolites of 6-Bnz-cAMP please inquire. Site-selective and membrane-permeant activator of cAMP-dependent protein kinase (cAK) which does not activate Epac and thus can be used as an Epac-negative control. Increased metabolic stability against PDE compared to cAMP. Selects site A of both cAK isozymes and thus can be used for synergistic activation of type II when combined with site B II- selective analogues such as Sp-8-CPT-cAMPS
(Cat. No. C 012) or 8-PIP-cAMP
(Cat. No. P 002). For preferential stimulation of cAK type I a combination with the site B I-selective analogue 2-Cl-8-MA-cAMP
(Cat. No. C 080) or 8-HA-cAMP
(Cat. No. H 006) can be used. For more details on site selectivity please inquire. Detailed technical information and updated reference list available. References: Christensen et al., J. Biol. Chem
, 35394 - 35402 (2003); Bos, Trends Biochem. Sci., 31, 680 - 686 (2006).